4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-025779
CHIEF FINANCIAL OFFICER sold 6,250 shares at an average $28.56 ($178,485)
- CHIEF FINANCIAL OFFICER acquired 6,250 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hohl Benjamin · CHIEF FINANCIAL OFFICER
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-10-28 | Exercise or conversion : show line 1 in the form 10b5-1 | +6,250 | $2.48 | $15,500 | 6,250 | D |
| 2024-10-28 | Sale : show line 2 in the form 10b5-1 | −5,600 | $28.49 | $159,562 | 650 | D |
| 2024-10-28 | Sale : show line 3 in the form 10b5-1 | −650 | $29.11 | $18,922 | 0 | D |
| Open-market sales · 6,250 sh · avg $28.56 · $178,485 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-10-28 | Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) | −6,250 | 173,806 | D |
Loading xslF345X05/form4-10302024_101039.xml…